Sulanemadlin | CAS#1451199-98-6 | MDM4/2 inhibitor

MedKoo Cat#: 465668 | Name: Sulanemadlin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sulanemadlin, also known as ALRN-6924 is a novel dual MDM4 and MDM2 inhibitor. ALRN-6924 is a "stapled peptide" that mimics the N-terminal domain of the p53 tumor suppressor protein. It binds with high affinity to both MDM2 and MDMX (also known as MDM4), the endogenous inhibitors of p53, to activate p53 signaling in cells having a non-mutant, or wild-type TP53 genotype (TP53-WT). Iterative structure-activity optimization endowed ALRN-6924 with favorable cell permeability, solubility, and pharmacokinetic and safety profiles. Intracellular proteolysis of ALRN-6924 forms a long-acting active metabolite with potent MDM2 and MDMX binding affinity and slow dissociation kinetics. At high doses, ALRN-6924 exhibits on-mechanism anticancer activity in TP53-WT tumor models. At lower doses, ALRN-6924 transiently arrests the cell cycle in healthy tissues to protect them from chemotherapy without protecting the TP53-mutant cancer cells.

Chemical Structure

Sulanemadlin

CAS#1451199-98-6

Theoretical Analysis

MedKoo Cat#: 465668

Name: Sulanemadlin

CAS#: 1451199-98-6

Chemical Formula: C95H140N20O23

Exact Mass: 1929.0400

Molecular Weight: 1930.28

Elemental Analysis: C, 59.11; H, 7.31; N, 14.51; O, 19.06

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 550.00	2 Weeks
5mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1451199-80-6 2000293-14-9 1451199-98-6

Synonym

ALRN-6924; ALRN6924; ALRN 6924; Sulanemadlin;

IUPAC/Chemical Name

D-Alaninamide, 42,112-(7E)-7-undecene-1,11-diyl-N-acetyl-L-leucyl-L-threonyl-L-phenylalanyl-L-alanyl-L-α-glutamyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-glutaminyl-L-leucyl-D-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-

InChi Key

VDLGAZDAHPLOIR-RLPDZDIMSA-N

InChi Code

InChI=1S/C95H140N20O23/c1-50(2)44-69(106-60(13)117)88(133)113-76(59(12)116)91(136)111-72(46-61-30-24-23-25-31-61)90(135)115-95(15)43-29-22-20-18-16-17-19-21-28-42-94(14,92(137)105-58(11)82(127)103-56(9)81(126)102-55(8)80(125)101-54(7)79(124)100-53(6)78(123)99-52(5)77(97)122)114-89(134)70(45-51(3)4)108-84(129)67(38-40-74(96)119)107-83(128)57(10)104-86(131)73(48-63-49-98-66-33-27-26-32-65(63)66)110-87(132)71(47-62-34-36-64(118)37-35-62)109-85(130)68(112-93(95)138)39-41-75(120)121/h17,19,23-27,30-37,49-59,67-73,76,98,116,118H,16,18,20-22,28-29,38-48H2,1-15H3,(H2,96,119)(H2,97,122)(H,99,123)(H,100,124)(H,101,125)(H,102,126)(H,103,127)(H,104,131)(H,105,137)(H,106,117)(H,107,128)(H,108,129)(H,109,130)(H,110,132)(H,111,136)(H,112,138)(H,113,133)(H,114,134)(H,115,135)(H,120,121)/b19-17+/t52-,53+,54+,55+,56+,57+,58+,59-,67+,68+,69+,70+,71+,72+,73+,76+,94+,95-/m1/s1

SMILES Code

C(C=1C=2C(NC1)=CC=CC2)[C@@H]3NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@](NC([C@H](CC5=CC=CC=C5)NC([C@@H](NC([C@H](CC(C)C)NC(C)=O)=O)[C@@H](C)O)=O)=O)(C)CCCCCC/C=C/CCC[C@](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(N)=O)C)=O)C)=O)C)=O)C)=O)C)=O)C)=O)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC3=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,930.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren JG, Sutton D, Olson KA, Packman K, Darlak K, Elkin C, Feyfant E, Kesavan K, Gangurde P, Vassilev LT, Nash HM, Vukovic V, Aivado M, Annis DA. Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development. J Med Chem. 2023 Jul 13. doi: 10.1021/acs.jmedchem.3c00623. Epub ahead of print. PMID: 37439511. 2: Ishikawa R, Saito K, Misawa T, Demizu Y, Saito Y. Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro. Biomolecules. 2023 Jun 16;13(6):1002. doi: 10.3390/biom13061002. PMID: 37371582; PMCID: PMC10296347. 3: Falandry C, List A, Balducci L. Cell cycle arrest: A breakthrough in the supportive care of older cancer patients. J Am Geriatr Soc. 2023 Jul;71(7):2297-2307. doi: 10.1111/jgs.18350. Epub 2023 Apr 10. PMID: 37036091. 4: Balducci L, Falandry C, List A. A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest. Drugs Aging. 2023 Mar;40(3):263-272. doi: 10.1007/s40266-022-01005-1. Epub 2023 Jan 30. PMID: 36715830. 5: Balducci L, Falandry C, List A. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology. Curr Oncol Rep. 2022 Dec;24(12):1695-1703. doi: 10.1007/s11912-022-01324-x. Epub 2022 Aug 20. Erratum in: Curr Oncol Rep. 2022 Nov 3;: PMID: 35986858. 6: Sidorova OA, Sayed S, Paszkowski-Rogacz M, Seifert M, Camgöz A, Roeder I, Bornhäuser M, Thiede C, Buchholz F. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. Cells. 2022 Mar 2;11(5):854. doi: 10.3390/cells11050854. PMID: 35269477; PMCID: PMC8909053. 7: Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Walensky LD, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2022 Jan 15;28(2):429. doi: 10.1158/1078-0432.CCR-21-4241. Erratum for: Clin Cancer Res. 2021 Jul 22;: PMID: 35045962. 8: Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 Oct 1;27(19):5236-5247. doi: 10.1158/1078-0432.CCR-21-0715. Erratum in: Clin Cancer Res. 2022 Jan 15;28(2):429. PMID: 34301750; PMCID: PMC9401461. 9: Zhang S, Lou J, Li Y, Zhou F, Yan Z, Lyu X, Zhao Y. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions. J Med Chem. 2021 Aug 12;64(15):10621-10640. doi: 10.1021/acs.jmedchem.1c00940. Epub 2021 Jul 21. PMID: 34286973. 10: Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, Zhan Y, Oliveira MMS, Westerberg LS, Annis DA, Johnsen JI, Selivanova G. Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. Cancer Discov. 2021 Dec 1;11(12):3090-3105. doi: 10.1158/2159-8290.CD-20-1741. PMID: 34230007; PMCID: PMC9414294. 11: Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell. 2021 Apr 12;39(4):529-547.e7. doi: 10.1016/j.ccell.2021.02.006. Epub 2021 Mar 4. PMID: 33667384; PMCID: PMC8575661. 12: Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam F. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 Mar 4;23(1):29. doi: 10.1186/s13058-021-01406-x. PMID: 33663585; PMCID: PMC7934277. 13: Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791. doi: 10.1016/j.blre.2020.100791. Epub 2020 Dec 27. PMID: 33423844. 14: Eskandari M, Shi Y, Liu J, Albanese J, Goel S, Verma A, Wang Y. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor. Leuk Lymphoma. 2021 Jan;62(1):167-175. doi: 10.1080/10428194.2020.1817441. Epub 2020 Sep 14. PMID: 32924682. 15: Kannan S, Partridge AW, Lane DP, Verma CS. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors. Int J Mol Sci. 2019 Nov 28;20(23):5996. doi: 10.3390/ijms20235996. PMID: 31795143; PMCID: PMC6928821. 16: Liao G, Yang D, Ma L, Li W, Hu L, Zeng L, Wu P, Duan L, Liu Z. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. Eur J Med Chem. 2018 Nov 5;159:1-9. doi: 10.1016/j.ejmech.2018.09.044. Epub 2018 Sep 18. PMID: 30253242. 17: Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 May 22;9(1):2024. doi: 10.1038/s41467-018-04356-9. PMID: 29789628; PMCID: PMC5964252. 18: Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003. PMID: 29643228; PMCID: PMC6130841.